Evidence map›Paper›PMID 39441542›Full record

ReviewInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2025

Lipschütz ulcer following first dose of COVID-19 tozinameran vaccine: Report of a case and review of a World Health Organization pharmacovigilance database.

Elliot Ewig, Nouha Ben Othman, Delphine Viard, Pierre-Alexis Gauci, Fanny Rocher, Milou-Daniel Drici

Abstract readCase ReportsReview
In one paragraph

Review in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Lipschütz ulcer following first dose of COVID-19 tozinameran vaccine: Report of a case and review of a World Health Organization pharmacovigilance database.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elliot EwigDepartment of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France.
Nouha Ben OthmanDepartment of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France.ORCID https://orcid.org/0000-0002-9346-5020
Delphine ViardDepartment of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France.
Pierre-Alexis GauciDepartment of Gynecology, University Hospital of Nice, Nice, France.
Fanny RocherDepartment of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France.
Milou-Daniel DriciDepartment of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France.ORCID https://orcid.org/0000-0003-4121-530X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipschütz ulcer (LU) is a condition known for painful vulvar ulcers, typically affecting young women and often linked to infectious agents. Recent reports have indicated a potential connection between LU and COVID-19 vaccination, particularly after the second or booster doses. This study presents a case of LU following the first dose of tozinameran in a young woman who had a previous SARS-CoV-2 infection and investigates similar cases globally. An 18-year-old woman experienced vulvar pain and ulcers 2-days after her initial COVID-19 vaccine dose. After ruling out infections through serological tests, a diagnosis of LU was made, and her symptoms resolved after 10 days. A literature search and VigiBase® analysis revealed 11 cases of LU following COVID-19 vaccination, and 519 vulvovaginal ulcer cases associated with these vaccines were identified in Vigibase®, with a median onset of 2 days. Most LU cases occurred after the second dose or booster shots. The primary hypothesis for this association is a type 3 hypersensitivity reaction mediated by immune complexes, possibly triggered by prior exposure, as many cases occurred after the second dose. Interestingly, the presented case suggests that prior COVID-19 infection could serve as sensitization. In conclusion, this study highlights the potential occurrence of LU after the initial COVID-19 vaccine dose in young patients with prior COVID-19 infection. While the risk of recurrence after subsequent vaccinations or infections remains uncertain, the benefits of vaccination outweigh the risks. Clinicians and patients should be aware of this potential issue to make informed decisions regarding vaccination.

Indexed as

COVID-19COVID-19 VaccinesUlcerVulvar DiseasesAdolescentBNT162 VaccineDatabases, FactualFemaleHumansPharmacovigilanceSARS-CoV-2World Health OrganizationBNT162 VaccineCOVID-19 Vaccinesadverse drug reactionCOVID‐19 vaccineLipschütz ulcersensitizationtozinameranvulvar ulcers

Identifiers

PMID39441542
PMCPMC11823353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.